Cannabidiol and cannabigerol limit l-dopa-induced dyskinesia when given separately or in combination to hemiparkinsonian rats (2024)
- Authors:
- USP affiliated authors: MARANGONI, GLAUCE CRIVELARO DO NASCIMENTO - FORP ; CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP ; GUIMARÃES, FRANCISCO SILVEIRA - FMRP ; GUIMARAES, ELAINE APARECIDA DEL BEL BELLUZ - FORP ; MATTOS, BIANCA ANDRETTO DE - FMRP
- Unidades: FORP; FMRP
- DOI: 10.1016/j.ibneur.2023.08.675
- Subjects: CANABINOIDES; DOENÇA DE PARKINSON; ANTI-INFLAMATÓRIOS; ANTIOXIDANTES
- Language: Inglês
- Imprenta:
- Source:
- Título: IBRO Neuroscience Reports
- ISSN: 2667-2421
- Volume/Número/Paginação/Ano: v. 15, supl. 1, p. S359, 2023
- Conference titles: World Congress of Neuroscience IBRO
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
MATTOS, Bianca Andretto de et al. Cannabidiol and cannabigerol limit l-dopa-induced dyskinesia when given separately or in combination to hemiparkinsonian rats. IBRO Neuroscience Reports. Amsterdam: Faculdade de Odontologia de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.ibneur.2023.08.675. Acesso em: 26 jan. 2026. , 2024 -
APA
Mattos, B. A. de, Nascimento, G. C. do, Crippa, J. A. de S., Hallak, J. E. C., Michel, P., Raisman-Vozari, R., et al. (2024). Cannabidiol and cannabigerol limit l-dopa-induced dyskinesia when given separately or in combination to hemiparkinsonian rats. IBRO Neuroscience Reports. Amsterdam: Faculdade de Odontologia de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.ibneur.2023.08.675 -
NLM
Mattos BA de, Nascimento GC do, Crippa JA de S, Hallak JEC, Michel P, Raisman-Vozari R, Guimarães FS, Del Bel EA. Cannabidiol and cannabigerol limit l-dopa-induced dyskinesia when given separately or in combination to hemiparkinsonian rats [Internet]. IBRO Neuroscience Reports. 2024 ; 15 S359.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1016/j.ibneur.2023.08.675 -
Vancouver
Mattos BA de, Nascimento GC do, Crippa JA de S, Hallak JEC, Michel P, Raisman-Vozari R, Guimarães FS, Del Bel EA. Cannabidiol and cannabigerol limit l-dopa-induced dyskinesia when given separately or in combination to hemiparkinsonian rats [Internet]. IBRO Neuroscience Reports. 2024 ; 15 S359.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1016/j.ibneur.2023.08.675 - Correction: Fluorinated cannabidiol derivatives: enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects
- Fluorinated Cannabidiol derivatives: enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects
- Cannabigerol mitigates haloperidol-induced vacuous chewing movements in mice
- Biological bases for a possible effect of cannabidiol in Parkinson’s disease
- Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning?
- Effects of minocycline on regional cerebral blood flow in schizophrenia
- Possible therapeutic uses of cannabidiol in anxiety disorders and schizophrenia
- Cannabidiol, a cannabis sativa constituent, as an antipsycholic drug
- Canabidiol: possíveis aplicacões terapêuticas em psicopatologias
- A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation
Informações sobre o DOI: 10.1016/j.ibneur.2023.08.675 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003252811.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
